Total Payments
$1.1M
2024 Payments
$127,282
Companies
27
Transactions
891
Medicare Patients
3,646
Medicare Billing
$1.1M
Payment Breakdown by Category
Other$776,424 (70.0%)
Consulting$117,587 (10.6%)
Research$102,546 (9.3%)
Travel$96,859 (8.7%)
Food & Beverage$14,883 (1.3%)
Education$192.43 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $727,024 | 235 | 65.6% |
| Consulting Fee | $117,587 | 32 | 10.6% |
| Unspecified | $102,546 | 25 | 9.3% |
| Travel and Lodging | $96,859 | 255 | 8.7% |
| Honoraria | $47,713 | 23 | 4.3% |
| Food and Beverage | $14,883 | 311 | 1.3% |
| Grant | $1,181 | 3 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $507.08 | 3 | 0.0% |
| Education | $192.43 | 4 | 0.0% |
Payments by Type
General
$1.0M
866 transactions
Research
$102,546
18 transactions
Ownership
$0
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $232,562 | 145 | $0 (2024) |
| Janssen Biotech, Inc. | $199,789 | 251 | $0 (2024) |
| Amgen Inc. | $137,460 | 120 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $128,055 | 91 | $0 (2017) |
| GlaxoSmithKline, LLC. | $101,072 | 43 | $0 (2022) |
| GENZYME CORPORATION | $74,973 | 56 | $0 (2024) |
| Ichnos Sciences Inc. | $51,392 | 6 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $46,373 | 28 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $44,315 | 30 | $0 (2024) |
| IGI Inc | $33,985 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $127,282 | 134 | Janssen Biotech, Inc. ($55,682) |
| 2023 | $105,759 | 117 | Janssen Biotech, Inc. ($71,091) |
| 2022 | $165,285 | 122 | GlaxoSmithKline, LLC. ($49,700) |
| 2021 | $135,981 | 68 | Ichnos Sciences Inc. ($38,334) |
| 2020 | $100,022 | 60 | Amgen Inc. ($24,547) |
| 2019 | $167,912 | 120 | Takeda Pharmaceuticals U.S.A., Inc. ($80,253) |
| 2018 | $123,061 | 108 | Takeda Pharmaceuticals U.S.A., Inc. ($87,994) |
| 2017 | $183,191 | 162 | Millennium Pharmaceuticals, Inc. ($128,055) |
All Payment Transactions
891 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $33.34 | General |
| 12/03/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $592.77 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | Cash or cash equivalent | $9.97 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,390.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Honoraria | Cash or cash equivalent | $3,875.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Travel and Lodging | Cash or cash equivalent | $80.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $121.91 | General |
| Category: Oncology | ||||||
| 11/12/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,571.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $437.78 | General |
| Category: Oncology | ||||||
| 11/12/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $155.69 | General |
| 10/31/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $36.68 | General |
| Category: Oncology | ||||||
| 10/31/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,571.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $121.39 | General |
| Category: Oncology | ||||||
| 10/24/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $22.78 | General |
| Category: Oncology | ||||||
| 10/24/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $13.38 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.92 | General |
| Category: Hematology | ||||||
| 10/08/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $34.73 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,070.00 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $135.25 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB 1342-101 | Ichnos Sciences Inc. | $51,392 | 6 |
| ISB 1342-101 | IGI Inc | $33,985 | 5 |
| An Open-Label, Dose-Escalation, Phase 1-2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment | Takeda Pharmaceuticals U.S.A., Inc. | $12,425 | 3 |
| CC-4047-MM-005 | Celgene Corporation | $2,533 | 1 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| TRILLIUM CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 620 | 3,420 | $500,358 | $203,070 |
| 2022 | 7 | 829 | 2,926 | $414,040 | $179,052 |
| 2021 | 10 | 1,126 | 4,579 | $652,960 | $348,413 |
| 2020 | 12 | 1,071 | 4,654 | $807,890 | $339,760 |
Total Patients
3,646
Total Services
15,579
Medicare Billing
$1.1M
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 279 | 745 | $224,036 | $110,422 | 49.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 124 | 436 | $131,052 | $52,139 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 115 | 194 | $46,394 | $21,129 | 45.5% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 19 | 1,920 | $75,340 | $11,269 | 15.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 24 | 32 | $7,604 | $2,716 | 35.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $5,300 | $1,896 | 35.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 20 | $3,044 | $1,589 | 52.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 11 | 11 | $3,881 | $1,279 | 33.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 20 | 50 | $3,707 | $630.00 | 17.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 281 | 694 | $208,200 | $101,010 | 48.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 130 | 392 | $117,600 | $47,685 | 40.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 93 | 160 | $40,000 | $16,718 | 41.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2022 | 15 | 940 | $18,800 | $5,879 | 31.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 248 | 652 | $19,560 | $4,811 | 24.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 14 | 14 | $6,860 | $2,303 | 33.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 22 | 40 | $2,000 | $427.97 | 21.4% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2022 | 26 | 34 | $1,020 | $217.21 | 21.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 297 | 748 | $224,400 | $113,534 | 50.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 120 | 656 | $104,960 | $105,042 | 100.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 121 | 413 | $123,900 | $52,312 | 42.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 89 | 218 | $54,500 | $24,305 | 44.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 56 | 247 | $49,400 | $22,342 | 45.2% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2021 | 14 | 1,240 | $24,800 | $8,302 | 33.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 311 | 915 | $27,450 | $6,971 | 25.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 40 | 40 | $19,600 | $6,568 | 33.5% |
About Dr. David Vesole, MD
Dr. David Vesole, MD is a Hematology healthcare provider based in Hackensack, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1790773356.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Vesole, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $127,282 received in 2024. These payments were reported across 891 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($727,024).
As a Medicare-enrolled provider, Vesole has provided services to 3,646 Medicare beneficiaries, totaling 15,579 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Hackensack, NJ
- Active Since 10/07/2005
- Last Updated 01/26/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1790773356
Products in Payments
- NINLARO (Drug) $345,169
- DARZALEX (Biological) $160,855
- Kyprolis (Biological) $74,392
- BLENREP (Biological) $65,173
- SARCLISA (Biological) $61,801
- Kyprolis (Drug) $50,591
- TECVAYLI (Biological) $50,084
- XPOVIO (Drug) $44,315
- Revlimid (Drug) $30,759
- EMPLICITI (Biological) $21,702
- Pomalyst (Drug) $13,293
- ISB 1342-101 (Drug) $8,197
- MOZOBIL (Drug) $6,760
- XGEVA (Biological) $6,300
- Nplate (Biological) $6,171
- CD38 (Drug) $4,394
- Venclexta (Drug) $4,346
- FARYDAK (Drug) $3,502
- VELCADE (Drug) $3,023
- ELREXFIO (Drug) $1,270
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Hackensack
Dr. James Mccloskey, M.d, M.D
Hematology — Payments: $2.8M
Hematology $2.8M
Dr. Jamie Koprivnikar, M.d, M.D
Hematology — Payments: $1.5M
Hematology $1.5M
Dr. Andrew Pecora, Md, MD
Hematology — Payments: $1.4M
Hematology $1.4M
Dr. Lori Leslie, M.d, M.D
Hematology — Payments: $669,511
Hematology $669,511
Dr. Robert Alter, Md, MD
Hematology — Payments: $539,884
Hematology $539,884
Dr. David Siegel, Md, MD
Hematology — Payments: $469,559
Hematology $469,559